Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants.

(iScience, v27.9:110728)

CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months. The third vaccine dose of mRNA-1273 in naive participants previously vaccinated with ChAdOx1-S/BNT162b2 regimen reached higher neutralizing antibodies titers against the variants of concern Delta and BA.1 lineage of Omicron compared with those receiving a third dose of BNT162b2 at day 28. These differences between BNT162b2 and mRNA-1273 arms were observed against the ancestral variant G614 at day 90. Suboptimal neutralizing response was observed against BQ.1.1, XBB.1.5/XBB.1.9, and JN.1 in a relevant proportion of individuals 180 days after the third dose, even after asymptomatic Omicron breakthrough infections. EudraCT (2021-001978-37); ClinicalTrials.gov (NCT04860739).

Read publication

Overview publication

Title	Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants.
Date	2024-09-20
Issue name	iScience
Issue number	v27.9:110728
DOI	10.1016/j.isci.2024.110728
PubMed	39286494
Authors	García-Pérez J, Borobia AM, Pérez-Olmeda M, Portolés A, Castaño L, Campins-Artí M, Bertrán MJ, Bermejo M, Arribas JR, López A, Ascaso-Del-Rio A, Arana-Arri E, Fuentes Camps I, Vilella A, Cascajero A, García-Morales MT, Castillo de la Osa M, Pérez Ingidua C, Lora D, Jiménez-Santana P, Pino-Rosa S, Gómez de la Cámara A, De La Torre-Tarazona E, Calonge E, Cruces R, Belda-Iniesta C, Alcamí J, Frías J, Carcas AJ & Díez-Fuertes F
Info	CombiVacS Study Group, García LD, García ER, Meseguer ES, Stewart Balbàs SM, Candón AM, García IG, Elizalde MU, Rosa P, García MS, Crespo CL, Martínez VM, de Madariaga Castell R, Vara LV, Prieto-Pérez R, Vargas-Castrillón E, Laredo L, Zhu-Huang O, Iglesias T, Imaz-Ayo N, Meijide S, García de Vicuña A, Santorcuato A, Exposito I, de Benito S, Bustinza A, Gallego M, García-Vázquez D, Belén de la Hoz A, Pérez-Nanclares G, Aurrekoetxea J, Urrutia I, Martínez-Salazar R, Orcajo J, Calvo B, Corcuera J, Velasco O, Aguayo A, Martínez-Gómez X, Otero-Romero S, Armadans L, Borras-Bermejo B, Parés O, Uriona S, Rodrigo Pendás JÁ, Llorente C, Santos J, Pinós L, Camacho L, Riera J, Sans C, Agustí A, Altadill C, Blancafort CA, Serrat GG, Plaza A, Prius AF, Torrens MM, Palacio E, Torres G, Calonge J, Alins EB, Pérez-Esquirol E, Bosch LV, Aldea M, Mellado E, Marcos MÁ, Tortajada M, Barón-Mira LE, Granés L, Lazaar S, Herranz S, Malet M, Quesada S, Llupià A, Olivé V, Trilla A, Gómez B, González E, Romero S, Gámez FJ, Casals C, Burunat L, Castelló JJ, Fernández P, Bedini JL, Vila J, Hurtado JC, Jado I, Fedele G, Perea C, González M, Grajera I, Murillo MÁ, Balfagón P, Díaz-Marín I, González-Pardo G
Keywords	Immune response, Immunology
Read	Read publication